Trovagene raises $15 million in direct offering

Diagnostic company Trovagene Inc. (NASDAQ:TROV) raised $15 million through the sale of 2.1 million shares at $7 in a registered direct offering to an institutional investor. In March, Trovagene launched its HPV-HR assay in the U.S. to detect HPV. The assay detects DNA sequences of 15 high-risk HPV strains from urine specimens and is conducted at Trovagene's CLIA-certified and CAP-accredited lab. ...